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EXECUTIVE SUMMARY 
Prescription drug coverage created by Title I of the Medicare Prescription Drug,  
Improvement, and Modernization Act of 20031 (MMA), also known as Medicare Part D, will 
affect not only 35.4 million elderly enrollees but also 6.5 million younger enrollees with 
disabilities, 2.4 million of whom have low incomes and currently obtain medications through 
Medicaid. This younger dually eligible group includes participants in state Medicaid Buy-In 
programs, which are work incentive programs that allow certain people with disabilities to work 
and maintain Medicaid coverage. Most Medicaid Buy-In participants are dual eligibles who will 
transition from Medicaid drug coverage onto Part D on January 1, 2006. 
Because Part D was conceived primarily as a benefit for elders and presumably was 
designed with their needs in mind, it is important to examine how this younger group of 
beneficiaries with disabilities—who have significantly different, and often unstable, health 
conditions—may be impacted. Of particular concern is the possibility that low-income persons 
with disabilities who utilize large numbers and/or expensive types of drugs may be unable to get 
their needs met under the privately operated Part D prescription drug plans (PDPs). 
To explore the potential impact of Part D on these younger dual eligibles, we analyzed 
Medicaid claims data for three dually-eligible Kansas groups: elders, Buy-In participants, and 
other disabled adults under age 65. Findings indicate that Buy-In and other disabled adults have 
fundamentally different health conditions and medication needs than the elderly, with Buy-In 
participants having the most intensive and expensive drug needs. Highlights include: 
• Average monthly prescription costs per person were $404 for Buy-In participants, 
compared to $387 for other dually-eligible persons with disabilities, $259 for young 
disabled persons eligible for Medicaid only, and $238 for dually-eligible elders. 
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• Buy-In participants have high rates of mental illnesses and use many expensive 
brand-name psychotropic medications, while elders have high rates of cardiovascular 
diseases and use more generics and over-the-counter medications. Other disabled 
dual eligibles, while also having high rates of mental illness, appear to have 
relatively higher rates of physical disabilities than Buy-In participants. 
• In the four classes for which off-label drug use was examined (antiulcer drugs, 
anticonvulsants, antidepressants, and antipsychotics), more than half (51.3%) of 
Buy-In enrollees used at least one medication for an other than FDA-approved 
indication.  
• Many Buy-In enrollees were discovered to use multiple drugs within a Part D class, 
with more than two-thirds (68.3%) using two or more drugs in at least one class and 
more than a quarter (26.5%) using three or more. 
People with disabilities are fundamentally different from the majority elder population 
enrolled in Medicare. With regard to Part D legislation, Buy-In participants use:  
• more high-cost medications, which may make it more difficult to access these drugs, 
given restrictive formularies and other cost-control practices;2
• more brand-name medications, making their Part D co-pay obligations higher;  
• many drugs off-label, increasing the likelihood that coverage for a prescribed 
medication may be denied;3 and  
• multiple drugs within classes, decreasing the likelihood that all of their medications 
will be covered by a single Part D plan. 
More than half of Kansas Buy-In participants previously qualified for Medicaid through 
the spenddown process; nationally, about one-third of Buy-In enrollees transitioned from this 
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eligibility category. Enrollment in Buy-Ins provides continuous access to Medicaid benefits 
without spending down income. Continuous access to medications through Medicaid Buy-In 
programs has proven to be a powerful incentive to work.4  In fact, a recent multi-state study 
found prescription drugs to be the single largest Medicaid benefit utilized by Buy-In 
participants.5 Under Part D, Buy-In participants who have Medicare coverage may feel less 
incentive to work and continue paying Buy-In premiums because they will no longer receive 
Medicaid drug coverage and, in fact, may be financially better off disenrolling. Moreover, if they 
are less able to gain access to needed medications under Part D, they may experience medical 
setbacks that make them less able to continue working. In either case, Part D will have the 
unintended consequence of acting as a barrier to work for thousands of people with disabilities. 
The fact that Medicare will risk-adjust premium subsidies according to socioeconomic 
status and health conditions suggests that the Centers for Medicare and Medicaid Services 
(CMS) is aware of the greater costs associated with some groups, particularly dual eligibles. 
However, the success of the proposed safeguards to protect both PDPs and beneficiaries remains 
to be seen. Because many details about Part D have yet to be determined, it is too early to predict 
how well the program will work for dual eligibles with disabilities. Other similar programs, 
however, provide some insights into likely problems. The introduction of managed care 
formularies for Medicaid recipients in Pennsylvania created many barriers for people to obtain 
essential medications in a timely manner.6 Given the managed care structure of Part D plans, 
similar problems seem likely; e.g., no provision of emergency supplies, waits of weeks to even 
months for approval of nonformulary prescriptions or those requiring prior authorization, and a 
host of other administrative issues. 
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Common sense suggests that a safety net is required for situations in which enrollees are 
unable to obtain critical or life-sustaining medications. Such situations can arise when either the 
drug is not on formulary and/or is being used off-label and the appeals process has been 
exhausted, or when patients cannot afford the co-payments for the numerous medications they 
need. Given the vulnerability of this population, immediate action is needed to address these 
issues in the short time remaining before Part D is implemented. 
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INTRODUCTION 
The prescription drug coverage created under Title I of the Medicare Prescription Drug, 
Improvement, and Modernization Act of 20037 (MMA), also known as Medicare Part D, will 
affect more than 40 million seniors and people with disabilities who are enrolled in Medicare. 
Some 2.4 million of these are individuals under age 65 with disabilities who, by virtue of their 
limited assets and income, are also eligible for Medicaid coverage. The people comprising this 
so-called dually-eligible disabled group currently access prescription drug coverage through their 
state Medicaid plans. Unfortunately, many of them may be disproportionately and negatively 
impacted when the Part D program is implemented in January 2006 and they are required to 
access medications through Medicare. Their drug utilization patterns are markedly different from
and their expenditures significantly higher than those of the seniors who constitute the majority of
people in Medicare; thus the formularies developed by private providers under Medicare Part D 
may be inadequate to meet their needs.  
To explore how dual eligibles may be affected, this paper discusses the medication needs 
and utilization patterns of an extremely vulnerable group, people with disabilities who are 
enrolled in the Kansas Medicaid Buy-In program. Buy-In programs allow qualified people with 
disabilities to work and maintain Medicaid eligibility. Although Buy-In enrollees account for 
only a small fraction of the potential Medicare Part D population (about 45,000 people 
nationally), the issues they present are illustrative of those that many dual eligibles with 
disabilities may face under the new Part D programs. Further, this study uses experiences in one 
state to highlight issues of potential importance to disabled Medicare beneficiaries nationwide. 
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Key Questions 
• How do the average per person, per month Medicaid pharmaceutical expenditures for 
Buy-In participants and other dually-eligible disabled populations differ from those of 
the elderly?  
• How do utilization patterns differ between dually-eligible persons with disabilities 
and the elderly in terms of classes of drugs used and the proportion of brand-name to 
generic drugs? Given these utilization patterns, will disabled participants experience a 
disproportionately greater financial impact from higher co-pays and out-of-pocket 
expenses under MMA? Will their utilization patterns place them at risk of not being 
able to access the drugs they need? 
• How often do Buy-In populations use certain classes of drugs for indications outside 
those approved by the FDA? Current guidance indicates that private drug plans will 
not be obligated to pay for drugs prescribed for off-label uses. 
• Do Buy-In participants tend to have high rates of prescription drug utilization within 
therapeutic classes? Under Part D, PDPs are required to provide only two drugs per 
category or class, based on the United States Pharmacopeia model guidelines that 
divide drugs into 146 categories and classes. How will this design affect 
beneficiaries’ access to the drugs they need?  
 
BACKGROUND ON MEDICAID BUY-IN PROGRAMS 
Medicaid Buy-In programs allow people with disabilities the opportunity to work and 
obtain or maintain Medicaid coverage. As of October 2004, 31 states operated Buy-Ins, an 
optional eligibility category under Medicaid.8 In the past dual eligibles with disabilities who 
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opted to work generally lost their eligibility for Medicaid coverage because Medicaid is a means-
tested program.9 Two pieces of legislation—the Balanced Budget Act of 1997 and the Ticket to 
Work/Work Incentives Improvement Act of 1999—gave states the flexibility to expand 
Medicaid to people with disabilities whose income or assets would otherwise disqualify them for 
coverage. The programs were designed as a work incentive to support increased employment and 
independence of people with disabilities who meet the standard for Social Security disability.  
Most states with Buy-In programs require cost-sharing for participants, usually through 
premiums based on a sliding fee scale. The majority (76%) of Buy-In participants are dually 
eligible for Medicare and Medicaid and will transition to the Part D benefit in January 2006. 10  
Despite the fact that some Buy-In participants may have incomes exceeding 100% of the 
federal poverty level, the regulations for the Medicare Modernization Act make it clear that Buy-
In participants are considered "full benefit dually-eligible" Medicaid participants and will thus 
qualify for the full Part D premium subsidy and reduced co-pays. The State of Kansas 
implemented its Medicaid Buy-In program, "Working Healthy," in July 2002 with funding from 
a Medicaid Infrastructure Change grant from the Centers for Medicare and Medicaid Services 
(CMS). Working Healthy allows Kansans with disabilities to work, increase their earnings and 
assets, and obtain or maintain Medicaid coverage. About half of participants in the program had 
qualified for Medicaid coverage through the state's medically needy program prior to enrollment 
in the Buy-In, and 98% are dually eligible.  
Recent compilations by Liu, Ireys, White and Black11 indicate that prescription drug costs 
are the single largest Medicaid expense for Buy-In participants. In California, pharmacy claims 
represented a full 74% of Buy-In expenditures.12 Comments from interviews and surveys of 
Kansas Buy-In participants have repeatedly and overwhelmingly underscored the fact that they 
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are better able to get their prescription medications because of enrollment in the Buy-In.13 “I 
really can’t afford my medicine any other way—even working,” writes one enrollee who has 
both diabetes and mental illness. “I 
get my meds for $12,” writes 
another. “Before, I was paying $200 
to $300 a month.” These same 
individuals frequently relate that 
their conditions are more stable 
because of consistent access to 
medications (see "A Buy-In 
participant who is able to work 
because of medications" inset).  
A Buy-In Participant Who Is Able to Work Because 
of Medications 
JB is a 51-year-old woman who has depression 
and bipolar disorder. She has been enrolled in the 
Kansas Buy-In since its inception, has worked 
continuously throughout her enrollment, and has even 
gone back to school to increase her work skills. Prior to 
the Buy-In, JB had a $1000+ spenddown every six 
months. 
“My biggest problem at the time was being able 
to keep my medication to be able to continue to work. 
That was the thing, if I wasn’t able to take my 
medication, then I was going to be at home. I wasn’t 
going to get out and do what I needed to do. And then I 
felt bad about myself and everything in life. And I’d get 
more depressed. So the medication part, being able to 
take my medication, is very important to be able to get 
to a place where I can work full time.” 
She also shared that, often, while in spenddown, 
"I didn't take my medication. I couldn't afford it." After 
enrolling, she said she has been "able to get my 
medication when I need it." She further related that, 
immediately after her enrollment, she spent a very 
difficult period of about six months becoming re-
stabilized through medication. Moreover, JB explained 
that, without her spenddown obligation, she has been 
able to pay off bills and feel less stressed financially. 
JB does not have extensive medication needs 
related to her mental illnesses—she takes Effexor XR 
and Geodon. She also regularly takes hormone 
replacement therapy and thyroid medication. 
Nevertheless, even short-term interruptions in her 
regimen can result in long-term setbacks to her quality 
of life and ability to work. Under Part D, JB will no 
longer have the option of accessing medications through 
Medicaid even if a Part D plan does not meet all of her 
needs. She will have the same coverage for 
prescriptions whether she works or not and, if the 
coverage is not adequate, may actually be unable to 
work.  
Depending on an individual 
Buy-In participant's motivations 
and needs, implementation of Part 
D may result in disincentives to 
work or barriers to work due to 
exacerbations of their conditions. 
Due to the complexity of the 
interplay between Medicaid and 
Medicare for dual eligibles, the 
exact effects of Part D are not yet 
clear. However, some potential 
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effects include the following: 
• Buy-In enrollees who pay a Buy-In premium, especially those who do not need many other 
Medicaid services, may find it more cost effective to disenroll once medications are 
available through Part D. 
• Individuals who leave the Buy-Ins may choose to work only at the income and asset levels 
that will keep them eligible for Part D premium subsidies.  
• Therapeutic interchange of less expensive and less effective drugs or other access problems
may result in destabilization of an individual's condition and inability to work competitively. 
 
METHODS 
To examine how Kansas Buy-In participants and other dually-eligible persons with 
disabilities might be affected by Part D, we analyzed one year of Medicaid claims data for three 
dually-eligible groups: elders, Buy-In participants, and other disabled adults under age 65.14 
Pharmaceutical claims provided information about the most commonly used and most expensive 
drugs as well as numbers of prescriptions filled and actual amounts paid by Medicaid. The Buy-
In group’s drugs also were classified within the United States Pharmacopeia Model Guidelines—
the suggested model for Part D formularies—and according to whether a generic version of the 
drug was available. These data were used to track the proportion of brand-name to generic 
utilization and the utilization of multiple drugs within Medicare classes. 
Information on disabilities was obtained in two ways. Self-reported disability 
declarations were available from a sample of Buy-In participants continuously enrolled in 2003. 
Outpatient and inpatient claims data were used to identify common comorbidities by aggregating 
ICD-9 (International Classification of Diseases, 9th revision) codes into 3-digit categories to 
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create major diagnostic categories. These data were available for all three groups. 
Description of the Sample 
Self-reported disabilities of Kansas Medicaid Buy-In participants are shown below. 
These data reflect 38% of all participants continuously enrolled throughout 2003; however, a 
similar distribution of conditions was found in an analysis of outpatient and hospital claims 
covering 98% of those continuously enrolled in 2003 (n=400). The disabilities shown below are 
those judged to be the most significant by the individual; 40% of participants report having 
multiple disabling conditions. Based on self-reports, people with mental illnesses constitute the 
single largest sub-group (53% of participants), followed by people with chronic physical health 
problems such as lupus, rheumatoid arthritis, and diabetes (14% of participants); people with 
cognitive impairments (13% of participants); and people with physical disabilities, such as 
cerebral palsy, paraplegia, amputations, or spinal conditions (11% of participants).  
Compared to the overall dually-eligible population in Kansas, people with serious mental 
illness are somewhat over-represented in the Buy-In. Buy-In programs in other states, including 
California,15 Minnesota,16 and Wisconsin17 have reported similar discrepancies for this sub-group. 
Self-Reported Primary Disability
for Buy-In Population
53%
11%
13%
6%
3%
14%
Psychiatric
Physical
Cognitive
Neurological
Sensory
Chronic Health
Conditions
 
Males and females are equally represented among Buy-In participants, and their average 
age is 44.9 years, ranging from a low of 21 to a high of 64 (program eligibility begins at age 16 
and ends at age 65). Again, this age range is fairly typical for Buy-Ins.18 Racially, 86.3% of 
participants are white, 5.3% are black, 3.1% are of another racial or ethnic minority, and 5.3% 
are unknown (see Table 1). This distribution approximates that of the state in general. The 
broader dually-eligible disabled population has proportionately more females and African 
Americans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
Demographic characteristics of Kansas Medicaid dually eligible participants by group 
Characteristic Percent of 
elders 
(n=4,482) 
Percent of Buy-
In participants  
(n=400) 
Percent of other 
 dually-eligible 
disabled  
(n=1,375) 
Gender    
Male 25.3 50.8 46.8 
Female 74.7 49.0 53.2 
Unknown 0.0 0.2 0.0 
    
Race/Ethnicity    
White 83.2 86.3 84.7 
Black 8.7 5.3 12.4 
Other 8.1 3.1 2.8 
Unknown 0.0 5.6 0.0 
    
Mean Age (SD) 79.7 (9.24) 44.9 (9.65) 45.7 (11.20) 
    
Age groups    
16-21 0.0 0.0 0.7 
21-30 0.0 6.3 10.4 
31-40 0.0 26.8 23.3 
41-50 0.0 37.8 30.2 
51-60 0.0 22 25.8 
61-64 0.0 6.8 9.5 
>=65 100.0 0.0 0.0 
Unknown 0.0 0.5 0.0 
Notes: Other Race/Ethnicity includes Hispanic, Native American, Asian, and other. Buy-In represents all members 
continuously enrolled during calendar year 2003; elderly and other dually-eligible disabled represent a cross-
sectional sample of persons enrolled at least one month from May 2001 through March 2002. 
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FINDINGS 
Table 2 reports comorbidities according to Medicaid claims, comparing the range of 
conditions experienced by the Buy-In enrollees with those of elders and other dually-eligible 
disabled Medicaid enrollees. Buy-In participants experience a range of chronic health conditions 
that are distinctly different from the types and frequencies of conditions experienced by dually-
eligible elders in the state; some of these conditions are related to the Buy-In group's underlying 
disabilities and some are related to their younger age. Notably, the most frequent mental disorder 
among elders is organic psychoses, including Alzheimer's disease and dementia, while Buy-In 
participants most frequently experience schizophrenia and other psychoses. Within chronic 
physical conditions, the elderly experience much more cardiovascular disease, whereas Buy-In 
participants have greater rates of diseases of the nervous system (e.g., multiple sclerosis) and 
systemic or inflammatory arthropathies (e.g., rheumatoid arthritis, systemic lupus 
erythematosus). People in the other dually-eligible disabled group are generally similar to those 
in the Buy-In group except that they have relatively higher occurrences of conditions—such as 
cerebral palsy, paralyses, and mental retardation—that likely qualify them for one of the state's 
home-and community-based services (HCBS) waivers. Waiver services, such as attendant care, are 
not yet available to Kansas Buy-In participants, so this discrepancy is not surprising. The differing 
distribution of conditions among the three groups significantly influences the types of 
medications used by each. 
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Table 2 
Major ICD category & principal diagnoses of Kansas participants by group  
 
 
 
 
ICD category & principal diagnoses 
 
 
Percent 
of elders 
(n=4,482)
 
Percent of 
Buy-In 
participants 
(n=400) 
Percent of 
other 
dually-eligible 
disabled 
(n=1,375) 
Infectious & parasitic diseases (000-041, 043-140) 11.8 10.5 11.5 
HIV infection (042)    0.0 1.0 0.6 
    
Neoplasms    
 Benign (210-229) 3.2 9.8 6.9 
 Malignant (140-209, 230-239) 8.2 5.3 6.0 
    
Endocrine diseases    
 Diabetes (250) 22.0 16.8 19.6 
 Hyperlipidemia (272) 8.8 8.3 11.9 
 Thyroid (240-246) 9.6 6.0 10.4 
    
Diseases of blood & blood-forming organs 
(280-289) 
14.0 4.0 11.7 
    
Mental Disorders    
 Organic psychotic conditions (290-294) 11.2 0.5 3.3 
 Schizophrenia (295) 3.1 27.3 13.6 
 Other psychoses (296-299) 7.6 25.3 21.5 
Neurotic disorders, including depression (300-316) 13.5 15.8 39.5 
 Mental retardation (317-319) 1.9 4.0 14.7 
    
Diseases of the nervous system & sense organs     
 Disorders of the eye and adnexa (360-379) 23.8 22.0 27.1 
 Disorders of the ear (380-389) 7.4 13.5 13.5 
 Multiple sclerosis (340-341) 0.2 1.3 2.1 
 Cerebral palsy and other paralytic syndromes 1.6 1.3 4.5
      Parkinson’s disease (332)                                                        3.9                   0.5                0.6 
continued
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Table 2 (continued) 
Major ICD category & principal diagnoses of Kansas participants by group 
 
 
 
 
ICD category & principal diagnoses 
 
 
Percent 
of elders 
(n=4,482)
 
Percent of 
Buy-In 
participants 
(n=400) 
Percent of 
other 
dually-eligible 
disabled 
(n=1,375) 
    
Diseases of the circulatory system    
Hypertensive disease (401-405) 38.3 16.3 27.4 
Ischemic heart disease, including myocardial 
infarctions (410-414) 
5.4 2.8 4.1 
Other heart disease, including heart failure (420-
429) 
30.9 6.5 15.8 
Cerebrovascular disease (430-438) 14.2 0.5 5.3 
    
Diseases of the respiratory system    
 Asthma (493) 3.5 10.3 8.1 
Other chronic obstructive pulmonary disease  
(491-492) 
5.8 2.5 5.6 
    
Diseases of the digestive system   
  
   
Diseases of the esophagus, stomach & duodenum 
(530-537)   
12.4 8.5 18.8 
    
Diseases of the genitourinary system    
Chronic renal disease, including renal failure  
(580-589)   
3.5 2.3 4.7 
Other genitourinary conditions (590-630) 21.6 24.0 31.1 
    
Diseases of the skin & subcutaneous tissue (680-710) 15.6 22.5 22.5 
    
Diseases of the musculoskeletal system & connective 
tissue 
   
Systemic & inflammatory arthopathies (710-714) 1.8 3.5 3.0 
Osteoarthritis & other joint disorders (715-719) 24.5 21.0 27.3 
Rheumatism, excluding the back (725-729) 13.8 20.8 24.7 
Dorsopathies (720-724) 11.2 15.0 18.8 
Osteopathies, chondropathies, & acquired 
musculoskeletal deformities (730-739) 
11.1 4.8 10.4 
Source: Kansas Medicaid Buy-In claims records, 2003; Kansas Medicaid elderly and disabled claims records, 2001-
2002. 
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Per Person Costs 
•  How do the average per person, per month Medicaid pharmaceutical expenditures for 
Buy-In participants and other dually-eligible populations with disabilities differ from those 
of the elderly?  
 
Table 3 summarizes the average per participant, per month Medicaid prescription drug 
costs of dually-eligible elders, Medicaid-only eligible persons with disabilities, dually-eligible 
persons with disabilities, and Buy-In participants in Kansas. Costs for dually-eligible persons 
with disabilities are 62% higher than those of elders, and costs for Buy-In participants are 70% 
higher than those of elders. The average per participant, per month cost of $404 for Buy-In 
participants is almost four times the estimated $109 national average monthly bid amount for 
Part D plans.19
 
Table 3 
Comparison of per participant per month Medicaid drug costs 
 
Population 
Average 
monthly cost 
Kansas Medicaid Buy-In $404 
Other dually-eligible disabled $387 
Medicaid-only disabled $259 
Dually-eligible elders $238 
Note: Costs are based on one year of expenditures; all are based on calendar year 2003. 
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Utilization Patterns, including Generic versus Brand-name 
• How do utilization patterns differ between dually-eligible persons with disabilities and 
the elderly in terms of classes of drugs used and the proportion of brand-name to 
generic drugs? Given these utilization patterns, will Buy-In participants experience a 
greater financial impact from higher co-pays and out-of-pocket expenses under MMA? 
Will their utilization patterns place them at risk of not being able to access the drugs 
they need? 
 
Using Medicaid administrative data, we compiled lists of the top 20 most frequently 
prescribed medications for Buy-In participants, dually-eligible elders, and other dually-eligible 
persons with disabilities. We also compiled lists of the 20 drugs accounting for the highest 
Medicaid drug expenditures, which reflect a combination of frequency of utilization and average 
cost of the drug. These lists are shown in Tables 4 through 6 and Tables 8 through 10.  
Antipsychotics, antidepressants and anticonvulsants account for 70% of the 20 most 
frequently prescribed drugs in the Buy-In population and 60% in the other dually-eligible group,
compared to 15% in the elderly dual-eligibles. Among the elderly, the distribution is 
quite different, with drugs used to treat cardiovascular conditions, ulcers, and pain accounting for 
80% of the most frequent classes. Only two antidepressants and one antipsychotic medication 
were among the top 20 for this population. Although the other dually-eligible disabled and Buy-
In populations have similar claims utilization, the former has somewhat higher frequency for 
physical conditions such as pain, cardiac, and respiratory conditions. 
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Table 4 
Most frequent prescriptions filled for Kansas Buy-In participants 
 
Rank 
Generic 
drug name 
Common trade 
name(s) 
 
Drug class 
Generic 
available 
1 Clozapine HCL Clozaril Antipsychotic Yes 
2 Levothyroxine Sodium Synthroid a Endocrine/Thyroid Yes 
3 Olanzapine Zyprexa Antipsychotic No 
4 Risperidone Risperdal Antipsychotic No 
5 Hydrocodone with 
Acetaminophen 
Vicodin, Vicodin ESb Analgesic Yes 
6 Divalproex Sodium Depakote, Depakote ER Anticonvulsant No 
7 Clonazepam Klonopin Anticonvulsant 
(benzodiazepine)c
Yes 
8 Sertraline HCL Zoloft Antidepressant No 
9 Quetiapine Fumarate Seroquel Antipsychotic No 
10 Venlafaxine HCL Effexor, Effexor XR Antidepressant No 
11 Bupropion HCL Wellbutrin, Wellbutrin 
SR, Wellbutrin XL 
Antidepressant Yes/Nod
12 Atorvastatin Calcium Lipitor Cardiovascular/ 
antilipemic 
No 
13 Paroxetine HCL Paxil, Paxil CR Antidepressant Yes/Nod
14 Gabapentin Neurontin Anticonvulsant Yes 
15 Cetirizine HCL Zyrtec Antihistamine No 
16 Lisinopril Prinivil, Zestril Cardiovascular/ 
Ace Inhibitor 
Yes 
17 Pantoprazole Sodium Protonix Antiulcer No 
18 Aripiprazole Abilify Antipsychotic No 
19 Trazodone Trazodone, Desyrel Antidepressant Yes 
20 Citalopram Hydrobromide Celexa Antidepressant Yes 
Notes: aOther names include Levothroid, Eltroxin, L-Thyroxine, Levotabs, Levoxyl, Levo-T, Unithroid. bOther 
names include Maxidone, Anexsia, Bancap HC, Lorcet, Lorcet Plus, Lortab, Zydone. cBenzodiazepines are excluded 
from payment under Medicare Part D but may still be covered under Medicaid with federal match. dSustained 
release (SR) or controlled release (CR) formulation remains under patent. Other forms available as generic. 
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Table 5 
Most frequent prescriptions filled for Kansas elderly Medicaid participants 
 
Rank 
Generic 
drug name 
Common trade 
name(s) 
 
Drug class 
Generic 
available 
1 Furosemide Lasix Diuretics Yes 
2 Potassium Chloride Slow Ka Potassium 
Replacement 
Yes 
3 Levothyroxine Sodium Synthroidb Endocrine/Thyroid Yes 
4 Digoxin Digitek, Lanoxin, Digicap Cardiovascular/ 
Inotropic 
Yes 
5 Aspirin  Analgesic, OTCd Yes 
6 Warfarin Sodium Coumadin Antiplatelet/ 
Anticoagulant 
Yes 
7 Celecoxib Celebrex Analgesic No 
8 Amlodipine Besylate Norvasc Cardiovascular/ 
Calcium Channel 
Blocker 
No 
9 Acetaminophen Tylenol, Genebs, Panadolc Analgesic, OTCd Yes 
10 Sertraline CL Zoloft Antidepressant No 
11 Propoxyphene/ 
Acetaminophen 
Darvocet, Wygesic Analgesic Yes 
12 Omeprazole Prilosec, Prilosec SA Antiulcer, OTCd Yes 
13 Lisinopril Prinivil, Zestril Cardiovascular/ 
Ace Inhibitor 
Yes 
14 Nitroglycerin Nitrobide Cardiovascular/ 
Vasodilators 
Yes 
15 Risperidone Risperdal Antipsychotic No 
16 Rofecoxib Vioxxf Analgesic No 
17 Ranitidine Zantac Antiulcer, OTCd Yes 
18 Famotidine Pepcid Antiulcer, OTCd Yes 
19 Atorvastatin Calcium Lipitor Cardiovascular/ 
antilipemic 
No 
20 Mirtazapine Remeron Antidepressant Yes 
Notes: aOther names include K Dur, Kaon Cl-10, Klor-Con, Klotrix, K+ 10, K-Norm, K-Tab, Micro K-10 
Ex, Pot Cl.  bOther names include Levothroid, Eltroxin, L-Thyroxine, Levotabs, Levoxyl, Levo-T, 
Unithroid.  cOther names include Mapap Acetam, Pediapap, Tempra 1 and Tempra 2. dOver-the-counter 
drugs are excluded from payment under Medicare Part D but may still be covered under Medicaid with 
federal match. eOther names include Nitroquick, Nitrolingual, Nitrol, Nitrodur, Nitrostat Sub, Deponit, 
Transderm NTG, Nitro Disc, Nitro Trans, Minitran TDS.  fWithdrawn from the market by manufacturer in 
2004. 
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Clearly, the types of drugs frequently used by younger dual eligibles and the elderly are 
quite different. From a policy perspective, an equally important finding is that, among these most 
frequently used drugs, only 50% of those for the Buy-In population are available as generics, 
compared to 70% of those used by elders and other dually-eligible disabled. This differential is 
accounted for in part by the higher concentration of psychotic disorders (for which brand-name 
atypical antipsychotics are often prescribed) among Buy-In participants. To investigate this issue 
Table 6 
Most frequent prescriptions filled for Kansas other dually-eligible participants 
 
Rank 
Generic 
drug name 
Common trade 
name(s) 
 
Drug class 
Generic 
available 
1 Levothyroxine Sodium Synthroida Endocrine/Thyroid Yes 
2 Hydrocodone with 
Acetaminophen 
Vicodin, Vicodin ESb Analgesic Yes 
3 Divalproex Sodium Depakote, Depakote ER Anticonvulsant No 
4 Olanzapine Zyprexa Antipsychotic No 
5 Clonazepam Klonopin Anticonvulsant 
(benzodiazepine) c
Yes 
6 Potassium Chloride Slow Kd Potassium 
Replacement 
Yes 
7 Furosemide Lasix Diuretics Yes 
8 Risperidone Risperdal Antipsychotic No 
9 Clozapine HCL Clozaril Antipsychotic Yes 
10 Phenytoin Sodium Dilantin, Phenytek Anticonvulsant Yes 
11 Omeprazole Prilosec, Prilosec SA Antiulcer, OTCe Yes 
12 Gabapentin Neurontin Anticonvulsant Yes 
13 Albuterol Proventil, Ventolin Bronchodilator Yes 
14 Sertraline HCL Zoloft Antidepressant No 
15 Quetiapine Fumarate Seroquel Antipsychotic No 
16 Estrogens, conjugated Premarin Hormone 
Replacement 
Yes 
17 Atorvastatin Calcium Lipitor Cardiovascular/ 
antilipemic 
No 
18 Trazodone Trazodone, Desyrel Antidepressant Yes 
19 Fluoxetine HCL Prozac Antidepressant Yes 
20 Paroxetine HCL Paxil, Paxil CR Antidepressant Yes/Nof
Notes: aOther names include Levothroid, Eltroxin, L-Thyroxine, Levotabs, Levoxyl, Levo-T, Unithroid. 
bOther names include Maxidone, Anexsia, Bancap HC, Lorcet, Lorcet Plus, Lortab, Zydone. 
cBenzodiazepines are excluded from payment under Medicare Part D but may still be covered under 
Medicaid with federal match. dOther names include K Dur, Kaon Cl-10, Klor-Con, Klotrix, K+ 10, K-
Norm, K-Tab, Micro K-10 Ex, Pot Cl. eOver-the-counter drugs are excluded from payment under Medicare 
Part D but may still be covered under Medicaid with federal match. fControlled release (CR) formulation 
remains under patent. Other forms available as generic. 
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further, we examined the usage of generic versus brand-name medications across all drugs used 
by the Buy-In population in 2003 (see Table 7). On average, 58.4% are brand-name. When the 
analysis is narrowed to maintenance drugs, fully 62.9% of medications used are brand-name, 
with an average 30.7 maintenance prescriptions filled annually per participant. For full benefit 
dually-eligible beneficiaries, the Part D co-pay for generic medications will be $1 and for brand-
name drugs $3, and these costs will increase each year. Under Medicaid, these individuals would 
be guaranteed access to their prescriptions regardless of their ability to meet a co-pay 
requirement. The same protection does not apply under Part D. 
Table 7 
Overall drug utilization profile for Kansas Buy-In participants for calendar year 2003 
 
Mean (SD) 
 
Participants 
Percent 
of total 
Used any prescription drug  378 94.5 
Used at least one maintenance druga  363 90.8 
    
Per person prescriptions per year (range 1-238) 56.5 (41.5)   
    
Per person maintenance prescriptions (range 1-216) 49.0 (35.3)   
     
Brand-name prescriptions
b 
33.1 (25.9)  58.4 
    
Brand-name maintenance prescriptions  30.7 (23.3)  62.9 
    
Unique drugs used per person per year (range 1-40)        10.7 (7.9)   
     
Persons using multiple drugs w/in a Medicare class    
 Two or more drugs per class  258 68.3 
 Three or more drugs per class   100 26.5 
Notes: N=400. aA maintenance drug is defined as one prescribed in minimum 25-day quantities. Also included are 
drugs prescribed repetitively in smaller doses that equate to a monthly supply. bDetermined by classifying 2003 
utilization according to United States Pharmacopeia model guidelines. 
 
Among the drugs that resulted in the highest cost to Medicaid, those used by the Buy-In 
and the other dually-eligible disabled populations are predominantly (70%) psychotropics: 
antipsychotics, antidepressants, anticonvulsants, and anxiolytics. For the Buy-In population two 
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A High-Cost User with Low Utilization 
of Psychotropic Drugs 
 
High cost drug users do not necessarily 
utilize large numbers of drugs or fill large 
numbers of prescriptions. The Buy-In 
participant with the third highest overall 
annual cost had claims of more than $17,500 
for monthly refills of only 3 maintenance 
drugs. Two of these were atypical 
antipsychotics (Seroquel and Zyprexa), and 
the third was a serotonin-specific reuptake 
inhibitor (Celexa). 
immunosuppressants also appear on the high cost list. Cardiovascular, antiulcer, and pain 
medications round out the top 20. For the elderly, the high cost drugs are more heterogeneous 
and include antipsychotics, analgesics, 
antiulcer agents, urinary tract 
antispasmodics, drugs used to treat 
cardiovascular conditions, and agents 
specific to the treatment of Parkinson's 
disease and dementia. The differences in 
high cost medications can be directly 
correlated with the conditions identified as 
more common within the two groups. More important from a policy perspective, though, is how 
responsive Part D formularies will be to the fundamentally different suite of high cost drugs used 
by the disabled population. 
Implications for Access 
CMS issued final guidelines for formularies that included a list of top drug classes by 
cost and utilization. CMS stated it would analyze the availability and tier positions of the drugs 
in this list "to ensure that plans are covering the most widely used medications for the most 
common conditions."20 Remarkably, that list did not include three classes encompassing four of the 
top 20 most costly drugs used by the Buy-In population: norepinephrine and dopamine reuptake
inhibitors (Wellbutrin); immunologic agents (Cellcept and Prograf), and glutamate reducing agents 
(Topamax).  
In the same guidance CMS also indicates that they expect formularies to contain a 
majority of available drugs for certain serious and potentially unstable conditions, 
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 including mental illness. Even if most or all of these drugs are on formularies, however, 
they could be placed on higher tiers, requiring beneficiaries to file a benefit appeal in 
order to access them. In addition, according to one legal scholar, “the final regulations 
preserve considerable discretion on the part of PDP sponsors to deny requests for 
exceptions to tiered cost sharing and formulary limits, even where the beneficiary 
submits written evidence from the prescribing physician satisfying the medical necessity 
standard applicable to such requests under law.”21  Beneficiaries themselves will have to 
contact their plans to initiate these appeals, which constitutes a potential barrier for low-
functioning individuals. In addition, they would be required to pay out of pocket the 
additional cost-sharing amount pending the appeal and would not be reimbursed if they 
were unsuccessful. Unlike Medicaid, Part D benefits do not continue pending appeal. 
Inability to pay these out-of-pocket costs on top of co-payments for Part D drugs, 
resulting in missed drugs, represents a substantial threat to medical stability and ability to 
continue in the labor force. 
Although formularies may start out with relatively generous benefits, nothing 
guarantees they will remain generous over time, especially as drug costs continue to rise. 
PDPs are allowed to remove drugs from formularies with a 60-day notice. Although full-
benefit dual eligibles are not locked into plans like other Medicare beneficiaries and may 
switch at any time, they may be unable to find a plan that better meets their needs. 
Beneficiaries also face potential additional out-of-pocket expenses for drugs previously 
paid for by Medicaid but excluded from Part D coverage. These include benzodiazepines, weight 
loss and weight gain agents, barbiturates, and over-the-counter drugs. Clonazepam, a type of 
benzodiazepine that is used to treat several psychiatric disorders, is the seventh most frequently 
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used medication by Kansas Buy-In enrollees and fifth most frequently used by other dual 
eligibles.22  States may choose to pay for excluded drugs and receive federal match (other than 
for over-the-counter drugs), but may be unable to do so given their obligation to pay the federal 
government a clawback payment for dual eligibles’ Part D coverage and recently legislated cuts 
in state Medicaid funding.   
In its final guidelines on formularies, CMS states that PDPs are expected to apply 
utilization management tools for cost control, such as step therapy and therapeutic 
interchange. Both the law and regulations make clear that a high use of generic 
medications is a goal for the Part D program.23,24 These drug utilization review practices 
represent a particular threat to Buy-In participants because they use more brand-name 
drugs (Tables 4-6). 
Buy-In participants and other dually eligible disabled persons have high rates of 
serious and persistent mental illnesses (SPMI). We found the mean annual cost of drug 
treatment for Buy-In participants with any SPMI diagnosis to be more than double the 
average for participants without SPMI ($6,183 vs. $2,829, p=.000). This is primarily due 
to the high cost of the newer antipsychotic agents and antidepressants, most of which are 
still under patent. These drugs are often considered the treatment of choice because of 
reduced side effects and, in some cases, greater effectiveness. However, the clinical 
superiority of these drugs has recently been questioned,25 and this fact in combination 
with their high costs makes them likely targets for utilization review and therapeutic 
interchange in Part D plans. Despite the fact that drugs within a class (e.g., serotonin-
specific reuptake inhibitors, atypical antipsychotics) may be regarded by Part D 
formularies as therapeutically equivalent, they have different side-effect profiles and 
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patient responses. The clinical substitution of older, lower-cost drugs could therefore be 
destabilizing and increase the risk of serious side effects.26 Kansas Buy-In participants 
have reported destabilization of their conditions when access to medications is 
interrupted.27
Dually eligible populations also have high rates of musculoskeletal and 
inflammatory conditions (Table 2), such as osteoarthritis, auto-immune diseases, 
rheumatism, and spinal diseases. At least 22 different nonsteroidal anti-inflammatory 
drugs (NSAIDs) are used in treating these conditions. The cost of a 30-day supply of 
these medications ranges from a few dollars to more than $100. The difference in anti-
inflammatory activity between different groups of NSAIDs is small; however, patient 
response is highly individualized, and trials of several drugs are often necessary before 
the right drug is found.28,29 If patients are unable to access the NSAID they need due to 
restrictive formularies or cost-control practices such as therapeutic interchange, increased 
pain or disease activity may lead to increased disability and inability to work. 
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Table 8 
Drugs accounting for the highest aggregate cost to Medicaid for Kansas Buy-in participants 
 
Rank 
Generic 
drug name 
Common trade 
name(s) 
 
Drug class 
Generic 
available 
1 Olanzapine Zyprexa Antipsychotic No 
2 Clozapine HCL Clozaril Antipsychotic Yes 
3 Risperidone Risperdal Antipsychotic No 
4 Quetiapine Fumarate Seroquel Antipsychotic No 
5 Aripriprazole Abilify Antipsychotic No 
6 Divalproex Sodium Depakote, Depakote ER Anticonvulsant No 
7 Topiramate Topamax Anticonvulsant No 
8 Ziprasidone HCL Geodon Antipsychotic No 
9 Venlafaxine HCL Effexor, Effexor XR Antidepressant No 
10 Gabapentin Neurontin Anticonvulsant Yes 
11 Buproprion HCL Wellbutrin, Wellbutrin 
SR, Wellbutrin XL  
Antidepressant Yes/Noa
12 Sertraline HCL Zoloft Antidepressant No 
13 Lansoprazole Prevacid Antiulcer No 
14 Tacrolimus Anhydrous Prograf Immunologic Agent No 
15 Simvastatin Zocor Cardiovascular/ 
Antilipemic 
No 
16 Paroxetine HCL Paxil, Paxil CR Antidepressant Yes/Noa
17 Pantoprazole Sodium Protonix Antiulcer No 
18 Atorvastatin Calcium Lipitor Cardiovascular/ 
Antilipemic 
No 
19 Citalopram 
Hydrobromide 
Celexa Antidepressant Yes 
20 Mycophenolate Mofetil Cellcept Immunologic Agent No 
Note: aSustained release (SR) or controlled release (CR) formulation remains under patent.  Other forms available as 
generic. 
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Table 9 
Drugs accounting for the highest aggregate cost to Medicaid for Kansas’s elderly participants 
 
Rank 
Generic 
drug name 
Common trade 
name(s) 
 
Drug class 
Generic 
available 
1 Olanzapine Zyprexa Antipsychotic No 
2 Omeprazole Prilosec, Prilosec SA Antiulcer, OTCa Yes 
3 Risperidone Risperdal Antipsychotic No 
4 Celecoxib Celebrex Analgesic No 
5 Sertraline HCL Zoloft Antidepressant No 
6 Lansoprazole Prevacid Antiulcer No 
7 Donepezil HCL Aricept Antidementia No 
8 Clopidogrel Bisulfate Plavix Antiplatelet/ 
anticoagulant 
No 
9 Potassium Chloride Slow Kb Potassium Replacement Yes 
10 Rofecoxib Vioxxc Analgesic No 
11 Mirtazapine Remeron Antidepressant Yes 
12 Amlodipine Besylate Norvasc Cardiovascular/ 
Calcium Channel Blocker 
No 
13 Atorvastatin Calcium Lipitor Cardiovascular/ 
antilipemic 
No 
14 Fentanyl Duragesic, Actiq Analgesic Yes 
15 Quetiapine Fumarate Seroquel Antipsychotic No 
16 Tolterodine Tartrate Detrol Urinary tract 
antispasmodic agent 
No 
17 Paroxetine HCL Paxil, Paxil CR Antidepressant Yes/Nod
18 Simvastatin Zocor Cardiovascular/ 
antilipemic 
No 
19 Gabapentin Neurontin Anticonvulsant Yes 
20 Carbidopa/Levodopa Sinemet, Sinemet CR Antiparkinson Agent Yes 
Notes: aOver-the-counter drugs are excluded from payment under Medicare Part D but may still be covered under 
Medicaid with federal match.  bOther names include K Dur, Kaon Cl-10, Klor-Con, Klotrix, K+ 10, K-Norm, K-Tab, 
Micro K-10 Ex, Pot Cl cWithdrawn from the market by manufacturer in 2004.dExtended release or controlled release 
formulation remains under patent.  Other forms available as generic.  
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Table 10 
Drugs accounting for the highest aggregate cost to Medicaid for Kansas other dually-
eligible participants 
 
Rank 
Generic 
drug name 
Common trade 
name(s) 
 
Drug class 
Generic 
available 
1 Olanzapine Zyprexa Antipsychotic No 
2 Phenytoin Sodium Dilantin, Phenytek Anticonvulsant Yes 
3 Risperidone Risperdal Antipsychotic No 
4 Divalproex Sodium Depakote, Depakote ER Anticonvulsant No 
5 Oxycodone HCL Oxycontin Analgesic Yes 
6 Quetiapine Fumarate Seroquel Antipsychotic No 
7 Omeprazole Prilosec, Prilosec SA Antiulcer, OTCa Yes 
8 Gabapentin Neurontin Anticonvulsant Yes 
9 Clozapine HCL Clozaril Antipsychotic Yes 
10 Fluoxetine HCL Prozac Antidepressant Yes 
11 Sertraline HCL Zoloft Antidepressant No 
12 Buspirone HCL Buspar Anxiolytic Yes 
13 Celecoxib Celebrex Analgesic No 
14 Lansoprazole Prevacid Antiulcer No 
15 Venlafaxine HCL Effexor, Effexor XR Antidepressant No 
16 Paroxetine HCL Paxil, Paxil CR Antidepressant Yes/Nob
17 Topiramate Topamax Anticonvulsant No 
18 Atorvastatin Calcium Lipitor Cardiovascular/antilipemic No 
19 Bupropion HCL Wellbutrin, Wellbutrin 
SR, Wellbutrin XL 
Antidepressant Yes/Nob
20 Rofecoxib Vioxxc Analgesic No 
Notes: aOver-the-counter drugs are excluded from payment under Medicare Part D but may still be covered under 
Medicaid with federal match .  bSustained release (SR) or controlled release (CR) formulation remains under patent. 
Other forms available as generic. cWithdrawn from the market by manufacturer in 2004. 
 
Off-Label Utilization of Drugs 
• How often do Buy-In populations use certain classes of drugs for indications outside 
those approved by the FDA? Current guidance indicates that private drug plans will 
not be obligated to pay for drugs prescribed for off-label uses. 
 
Nowhere in the regulations for MMA are Part D providers required to cover off-label 
utilization of drugs by plan participants. In fact, CMS states, "We do not have the authority to 
require that Part D plans cover the off-label use of certain Part D drugs."30 Plans will have 
flexibility to determine an acceptable use of a drug and the required documentation to support 
that use.   
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In order to gauge the extent of off-label drug utilization among Buy-In participants, we 
selected four classes of drugs that are commonly used for purposes other than the FDA-approved 
indication: anti-ulcer agents, anticonvulsants, antidepressants, and antipsychotics.31 We then 
aggregated all inpatient and outpatient ICD-9 codes for participants for calendar year 2003. A 
drug was considered to be used off-label if no supporting diagnosis was recorded for the year. 
The resulting off-label utilization counts are shown in Table 11. Over all, more than half of 
prescriptions for these medications were not supported by a recorded diagnosis code.32 This 
finding is even more troubling in light of the fact that these four classes account for the great 
majority of the 20 most expensive drugs used, making it likely that Part D providers will 
carefully scrutinize their usage, with the onus being on the physician—and patient—to fully and 
persuasively document the need. Other drugs were also used off-label within the Buy-In 
population. People with autoimmune conditions, such as lupus and rheumatoid arthritis, often 
use antineoplastic and immunosuppressant drugs. Strict adherence to FDA-approved uses would 
allow PDPs to refuse these expensive medications for these individuals (see also “A Buy-In 
Participant with Multiple Sclerosis,” page 30). 
Of course, PDPs may elect to cover drugs used for indications beyond those approved by 
the FDA. However, they are not required to do so. The standard industry practice is to use one of 
four federally-approved drug compendia that report potential therapeutic uses of each drug, 
including those discovered after FDA approval. These compendia are based on research reported 
in medical literature and at medical conferences. However, they vary widely in 
comprehensiveness. For instance, the Wall Street Journal reports that Drugdex, the most 
comprehensive compendium, contains 203 off-label uses for the 12 most popular drugs in the 
U.S., while AHFS Drug Information contains 68 and U.S. Pharmacopeia 9.33 Given the need to 
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control costs, PDPs may decide to exercise restrictive definitions of appropriate off-label use in 
basic benefit plans. 
A concern with any additional documentation requirements for prescriptions is that the 
added administrative burden will cause even fewer practitioners to accept publicly insured 
patients. Patients also may be reluctant to ask for this help. A study of California’s Medicaid 
Buy-In program cited a participant who was reluctant to ask for prior authorization because her 
doctor "does not get paid very much" and "she feels badly asking her doctor to do this."34
Table 11 
Rate of off-label drug use among Kansas Medicaid Buy-In participants 
 
Drug class 
Off-label 
users 
Total 
users 
Percent of  
off-label use 
Antiulcer drugs   80 109 73.4 
Anticonvulsants 105 153 68.6  
Antidepressants 104 210 49.5 
Antipsychotics   23 176 13.1 
Any off-label use in above classes 194 378 51.3 
Note: Off-label use is defined as any use outside FDA-labeled indication. Off-label use is computed as 
percent of those for whom drug was prescribed. 
 
Use of Multiple Drugs within a Class 
• Do Buy-In participants tend to have high rates of prescription drug utilization within 
therapeutic classes? Under Part D, PDPs are required to provide only two drugs per 
category or class, based on the United States Pharmacopeia model guidelines that 
divide drugs into 146 categories and classes. How will this design affect beneficiaries’ 
access to the drugs they need?  
 
Although PDPs have wide latitude in the design of their formularies, the CMS model 
guidelines require that a Part D plan cover a minimum of only two drugs within each therapeutic 
class, or one if there is only one drug in the class. Basic benefit plans could thus be very 
restrictive, with more generous benefits provided only for the critical classes identified by CMS 
(i.e., antidepressants, antipsychotics, anticonvulsants, antiretrovirals, immunosuppressants, and 
antineoplastics).
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30 people with MS make up a small percentage of the Buy-In population, the
rug costs and off-label use of medications present a good case study of the
of Part D on non-elderly persons with disabilities. At this writing, five 
g treatments for multiple sclerosis have been approved by the U.S. Food an
tion. None of these is currently available in generic form and their average 
1,382. Numerous other drugs are used off-label to treat the symptoms of M
in for spasticity, amitriptyline for pain, and SSRIs and amantadine for 
lans will likely have little incentive to compete for these high-cost users an
the mandatory two drugs in the MS-specific drug class. Moreover, the off-
 more carefully scrutinized to hold down overall costs and because less 
available to support the usage. 
nt here the utilization profile for a Buy-In participant with MS (see below)
 subject filled 81 prescriptions comprising 18 unique drugs. The total 
iture on these drugs was more than $15,000—substantially greater than the
 annual Part D participant cost of $1,308. The only medication used by this
 specific to MS is Copaxone, with an average monthly cost in our file of 
eflecting a lower Medicaid-negotiated rate than the higher retail price of 
alabresi.* This person's utilization is also remarkable in the off-label use of
f drugs we examined for off-label utilization and an additional fifth drug 
case. The first of these is amantadine, an antiviral medication used primaril
. It is also on-label in the treatment of Parkinson's disease. However, throug
n mechanism, amantadine is sometimes effective in treating the fatigue 
S. The second off-label prescription used by this subject is Neurontin, whi
leviate pain and spasticity. Our subject also used both Zyprexa and Zoloft, 
o psychiatric diagnoses recorded for the year. Depression is a common 
 but Zoloft can also be used to reduce MS-related fatigue. The final off-labe
n was for Protonix. During the year, she did use two ulcer-sparing NSAIDs
lebrex—perhaps indicating a tendency toward gastric symptoms, but one n
er claims records. 
 study also used a variety of medications for on-label treatment of both acu
itions, including hypertension and a bone fracture, as shown. One of the 
rly was sulfamethoxazole/trimethoprim, presumably as a prophylaxis again
ctions common in MS and also documented by diagnoses codes.  
ation profile for a Buy-In participant with Multiple Sclerosis  
Total  Times  Total  Times 
cost filled Medication cost filled  
$9264.59                  9           Tequin                            $115.32                   2 
        1,743.80                  7            Maxair Autoinhaler          80.12                   1 
  965.29 12 Sulfamethoxazole/ 
  849.50 6 Trimethoprim     62.68      12 
  595.93 9 Tramadol HCL       39.60       4 
  485.32 4 Percocet          34.23       1 
  300.60 3 Amantadine        5.99       1 
  295.45 3 Furosemide      3.05       2 
  190.90 2 Prednisone      2.15       1 
  138.38 2 Total  $15,172.90 81 
4). Diagnosis and management of multiple sclerosis. American Family Physican, 
. 
A Person with HIV Needing to Gain Weight 
 
The second-highest-cost individual in our 
Buy-In sample, with total drug expenditures 
exceeding $20,000 a year, is a person with HIV 
infection. Although this person used numerous 
costly anti-viral medications, the drug with the 
single highest cost per prescription was a weight-
gain agent, Oxandrin, an anabolic steroid costing 
more than $900. Oxandrin is specifically FDA-
approved for weight gain, a use that is categorically 
excluded under Part D regulations. In this case, 
however, it is being used for the treatment of HIV-
related wasting. The Part D regulations regarding 
this situation are somewhat ambiguous. On the one 
hand, they state that the definition of a Part D drug 
excludes "agents when used for anorexia, weight 
loss, or weight gain" (page 4360). On the other, they 
also allow excluded drugs to be covered when used 
for a medically accepted indication (e.g., weight 
loss drugs used to treat morbid obesity). CMS 
seems to recognize the potential complexity of the 
issue in its statement that an "IRE [independent 
review entity] may be called upon to review 
whether an agent was in fact used for anorexia, 
weight loss or weight gain (and therefore excluded 
from the definition of Part D drug), or whether it 
was used for some other purpose" (page 4360). 
Given the somewhat equivocal nature of the 
regulations on this topic and the potential high 
costs involved, PDPs might choose not to cover 
these medications.   
The individual we cite is currently able to 
work full time and pay a premium to maintain 
Medicaid coverage.  Should he, or anyone else with 
HIV, cancer, or other conditions that can result in 
wasting, be unable to access weight gain treatment, 
the ability to continue working competitively could 
be threatened. States have the option to continue 
covering drug classes excluded under Part D but 
may have limited ability to do so.   
More than two-thirds (68.3%) of Buy-In participants used at least two medications within at least 
one Medicare drug class. More than a quarter (26.5%) used three or more medications within at 
least one Medicare drug class. If the standard remains two drugs per class, then the odds increase 
that these individuals will not have 
coverage for all of their needed 
medications. 
 
DISCUSSION 
Part D legislation was passed "to 
provide for a voluntary program for 
prescription drug coverage";35 yet, for 
dually-eligible people with disabilities, 
participation is mandatory. Those who 
do not voluntarily enroll in a plan will 
be automatically enrolled and will not 
have the option to waive coverage and 
continue accessing drugs through 
Medicaid, even with their continued 
eligibility for Medicaid. Our findings 
indicate that the drug utilization 
patterns and costs for Medicaid Buy-In 
participants are fundamentally different 
from those of seniors. Moreover, their 
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utilization patterns put them at high risk for greater out-of-pocket costs and inability to find a Part 
D plan that matches their needs. 
First, the dually-eligible Buy-In population has substantially higher overall costs than 
other disabled populations and elders. In fact, Buy-In participants' per person drug costs 
approach four times the projected national average $109/month.36  Despite risk-adjustments that 
are designed to serve as safeguards, Part D plans will have little incentive to enroll these people 
with the highest drug costs. In addition, premium subsidies for dual eligibles will only cover 
enrollment in low-cost plans. Higher-cost, more comprehensive plans will require additional out-
of-pocket premium payments. 
Next, our findings indicate that the Buy-In population uses relatively more brand-name 
medications than do elders and other dually-eligible disabled. Much of this discrepancy is 
attributable to the different medical conditions experienced by the populations. Generics are 
simply not available in many of the drug classes more heavily utilized by Buy-In participants, 
such as MS-specific agents or many atypical antipsychotics. With a $1 co-pay for generics and a 
$3 co-pay for brand-names—in addition to simply needing more medications—the Buy-In 
participants will likely pay more out of pocket than will elders with similar income and asset 
levels. This inequity will likely grow as co-pay amounts increase over time. 
Buy-In participants also use many drugs off-label. CMS has stated unequivocally 
that it cannot require Part D plans to cover these uses. Although plans are required to have 
appeals processes in place for disputes regarding the appropriate use of a medication, the burden 
will be on patients and their physicians to prove medical necessity. Adding to the physician’s 
burden of treating dually-eligible persons is likely to further erode the number of physicians, 
especially specialists, willing to treat publicly insured populations. Moreover, if the appeal 
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results in a denial, the individual will be responsible for the full cost of the medication. 
Although Part D plans have wide discretion in designing their formularies, they are 
required to cover only a minimum of two drugs per therapeutic class. For people who use 
multiple drugs within a therapeutic class, this design could prove to be problematic. More than 
half of Buy-In participants use at least two drugs within a Medicare class and a quarter use three 
or more. This utilization pattern puts Buy-In participants at high risk for not having all of their 
medications covered by a particular provider.  
Despite the intention to increase access to medications for Medicare beneficiaries through 
Part D, many dual eligibles may actually experience decreased access. Current safety net 
provisions in the CMS regulations leave many holes through which dually-eligible disabled 
persons may fall. Coverage may not be as comprehensive as under Medicaid because, unlike 
Medicaid, Part D plans are not at financial risk for negative outcomes. Dual eligibles may benefit 
from utilization review for appropriate use of medications, but certain other drug utilization 
review practices, such as therapeutic interchange, may be detrimental to those with serious and 
unstable health conditions. Holes in the safety net in the form of non-covered drugs and higher 
co-pays for brand-name medications also increase out-of-pocket expenses for low-income dual 
eligibles and the risk for missed medications. For dual eligibles currently working and 
participating in Medicaid Buy-Ins, work incentive and ability to work may both be eroded.  
Immediate action is needed if these unintended consequences are to be avoided. 
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